Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vasculostatic agents and methods of use thereof

a vasculostatic agent and vascular technology, applied in the field of vascular dysfunction treatment, can solve the problems of loss of normal function, serious pathologic consequences of compromised vasculostasis, and adverse effects on tissue and organ function and ultimately survival, so as to reduce vascular leakage, inhibit or reduce vascular leakage, and reduce vascular leakage

Inactive Publication Date: 2007-09-06
TARGEGEN
View PDF19 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0115] In one embodiment, the invention provides a method for inhibiting or reducing vascular leakage in a subject, comprising administering to a subject in need thereof an effective amount of IL-2 in combination with a compound of Structure set forth in Structures I, II, III, IIIa, IV, V, VI or VII or any combination thereof., thereby reducing vascular leakage in the subject. In one aspect, the compound may be N-(2-(1H-Indol-2-yl)-phenyl)-phthalamic acid or 6,7-bis-(3-hydroxyphenyl)-pteridine-2,4-diamine.
[0116] In one embodiment, the invention provides a pharmaceutical composition comprising IL-2 and at least one compound as set forth in Structures I, II, III, IIIa, IV, V, VI or VII or any combination thereof, in a concentration effective to reduce vascular leakage associated with IL-2 administration.

Problems solved by technology

Compromised vasculostasis has serious pathologic consequences.
For example, if vascular permeability increases beyond manageable levels, the resulting edema may negatively impact tissue and organ function and ultimately survival.
In general, however, edema in any tissue or organ leads to some loss of normal function, and therefore to the risk of morbidity or even mortality.
Similarly, excessive endothelial proliferation may damage tissues (such as the retina in proliferative retinopathies) or fuel unwanted tissue growth (such as with tumor growth).
The cascade of events that leads to the loss of endothelial barrier function is complex and incompletely understood.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vasculostatic agents and methods of use thereof
  • Vasculostatic agents and methods of use thereof
  • Vasculostatic agents and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Syntheses of Vasculostatic Agents

Experimentals

General Analytical Methods

[0351] All solvents are used without further purification. Reactions are usually run without an inert gas atmosphere unless specified otherwise. All 1H NMR are run on a 500 MHz Bruker NMR. Chemical shifts are reported in delta (δ) units, parts per million (ppm) downfield from tetramethylsilane. Coupling constants are reported in hertz (Hz). A Water LC / MS system is used in identity and purity analysis. This system includes a 2795 separation module, a 996 photodidode array detector and a ZQ2000 mass spectrometer. A Zorbax SB column (150×4.6mm 3.5μ, Agilent Technologies) is used for the LC. Column temperature is 40° C. Compounds are separated using gradient elution with mobile phases of water (0.05%TFA (A)) and acetonitrile (0.05%TFA (B)). Flow rate is 1 mL / min. The gradient program used in separation is 0-15 min: 5-60% B; 15-15.5 min: 60-100% B; 15.5-17 min: 100% B.

[0352] The following gradient programs were...

example 2

Anti-Cancer Therapy with Vasculostatic Agents

[0640] The following experiments show the use of vasculostatic agents of the invention alone and in combination with chemotherapeutic agents for treatment of cancer. FIG. 2 shows the synergistic results of co-drug therapy utilitizing 6,7-bis(4-hydroxyphenyl)-pteridin-4-ylamine, sulfate salt, (compound A—in this example formulated in 50% PEG400:50% water) illustrated in FIG. 1, with doxorubicin (in this example formulated in 50% PEG400:50% water). In the experiment shown in FIG. 2, syngeneic Lewis lung carcinoma cells were injected I.V. in order to establish lung metastases in Balb / C mice. Beginning 10 days after cells were injected, doxorubicin (3 mg / kg) and / or 6,7-bis(4-hydroxyphenyl)-pteridin-4-ylamine, sulfate salt, (compound A—various doses as shown) was given I.P. every 3 days for 3 cycles. Animals were sacrificed at day 20, lungs were collected, and weighed. Net tumor burden is the weight of tumor-bearing lungs minus the average we...

example 3

Inhibition of Vascular Permeability

[0646] IL-2 is used clinically to treat metastatic melanoma and renal cell carcinoma and the dose-limiting toxicity for IL-2 is Vascular Leak Syndrome (VLS). Two representative examples from distinct chemotype series were selected for initial study in the reduction of IL-2-induced VLS (see FIG. 1 compounds). The compounds were pre-screened for in vivo reduction of vascular permeability and there was no observable gross toxicity as single agents at 20-fold higher doses.

[0647] The results of the studies shown in FIGS. 7-8 indicate that representative compounds of the invention show inhibition of vascular leak in vivo. There were no effects on T cell proliferation in prescribed dose range (see FIGS. 10-11) and no effects on anti-tumor activity of IL-2 (melanoma model; see FIG. 9). The following experiments exemplify the results for co-drug therapy.

[0648] BalbC mice were given 9 injections of the indicated dose of murine IL-2 (in this example formul...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Column temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia / reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult / acute respiratory distress syndrome (ARDS), and the like.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation application of U.S. application Ser. No. 10 / 679,209 filed Oct. 2, 2003, now pending; which claims the benefit under 35 USC §119(e) of U.S. Application Ser. Nos. 60 / 479,295 filed Jun. 17, 2003, 60 / 466,983 filed Apr. 30, 2003, 60 / 463,818 filed Apr. 17, 2003, 60 / 443,752 filed Jan. 29, 2003, 60 / 440,234 filed Jan. 14, 2003 and 60 / 415,981 filed Oct. 3, 2002. This disclosure each of the prior applications is considered part of and is incorporated by reference in the disclosure of this application.FIELD OF THE INVENTION [0002] The present invention relates generally to treating disorders associated with vascular functioning, and more specifically to compounds and methods of treating such disorders. BACKGROUND OF THE INVENTION [0003] The vascular system is a prime mediator of homeostasis, playing key roles in the maintainence of normal physiologic functioning. For example, the vascular endothelium's barrier fun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/5377A61K31/525A61K39/395A61K31/704A61K31/7048A61K31/337A61K31/404C07D209/14A61K31/405A61K31/724C07D209/02C07D209/04C07D209/48C07D239/88C07D239/90C07D239/95C07D241/42C07D253/10C07D401/12C07D403/12C07D405/04C07D405/12C07D471/04C07D487/04C07D519/00
CPCC07D209/14C07D209/48C07D239/88C07D239/90C07D239/95C07D241/42C07D487/04C07D401/12C07D403/12C07D405/04C07D405/12C07D471/04C07D253/10A61P11/00A61P11/06A61P17/02A61P19/02A61P27/02A61P29/00A61P35/00A61P37/06A61P43/00A61P9/00A61P9/10A61K31/404A61K31/498A61K31/519
Inventor WRASIDLO, WOLFGANGDOUKAS, JOHNROYSTON, IVORNORONHA, GLENNHOOD, JOHN D.DNEPROVSKAIA, ELENAGONG, XIANCHANGSPLITTGERBER, UTEZHAO, NINGNING
Owner TARGEGEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com